Growth for Tissue Therapies
Monday, 11 August, 2008
Brisbane biotech Tissue Therapies (ASX: TIS) has begun an early stage human trial of its VitraGro technology, aimed at the wound care market.
The first trial, being held at the Fremantle Hospital in WA, is for the treatment of venous ulcers, the major cause of chronic wounds. The company is also awaiting approval from Canadian health authorities for a clinical trial for venous, diabetic and pressure ulcers (bed sores).
VitroGro uses a synthetic version of naturally occurring protein that is normally present in the human body at injury sites, to deliver multiple recombinant growth factors. It is an animal product-free alternative to fetal bovine serum or serum-derived factors.
The technology was developed by Professor Zee Upton and colleagues at Queensland University of Technology's Institute of Health and Biomedical Innovation.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
